PALARETI, GUALTIERO
 Distribuzione geografica
Continente #
NA - Nord America 7.070
AS - Asia 5.948
EU - Europa 4.296
AF - Africa 324
SA - Sud America 303
OC - Oceania 37
Totale 17.978
Nazione #
US - Stati Uniti d'America 6.983
SG - Singapore 1.902
CN - Cina 1.563
VN - Vietnam 1.279
GB - Regno Unito 1.200
DE - Germania 649
IT - Italia 471
SE - Svezia 381
HK - Hong Kong 359
FR - Francia 341
UA - Ucraina 308
IN - India 289
RU - Federazione Russa 267
BR - Brasile 217
IE - Irlanda 166
NL - Olanda 158
JP - Giappone 123
ZA - Sudafrica 113
KR - Corea 111
FI - Finlandia 90
EE - Estonia 83
SC - Seychelles 67
PH - Filippine 49
CI - Costa d'Avorio 47
ID - Indonesia 47
CA - Canada 39
MX - Messico 36
AR - Argentina 34
JO - Giordania 34
TG - Togo 33
CH - Svizzera 30
AT - Austria 27
EG - Egitto 27
AU - Australia 24
TH - Thailandia 24
BD - Bangladesh 22
BE - Belgio 22
CZ - Repubblica Ceca 22
IQ - Iraq 22
GR - Grecia 18
PK - Pakistan 17
SA - Arabia Saudita 16
TR - Turchia 15
TW - Taiwan 15
PL - Polonia 14
BG - Bulgaria 13
CO - Colombia 13
MY - Malesia 13
NZ - Nuova Zelanda 13
MA - Marocco 10
UZ - Uzbekistan 10
CL - Cile 9
PY - Paraguay 8
ES - Italia 7
KE - Kenya 6
LB - Libano 6
PE - Perù 6
RO - Romania 6
UY - Uruguay 6
OM - Oman 5
PS - Palestinian Territory 5
DZ - Algeria 4
EC - Ecuador 4
TN - Tunisia 4
AL - Albania 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HR - Croazia 3
IL - Israele 3
IR - Iran 3
LT - Lituania 3
NG - Nigeria 3
AZ - Azerbaigian 2
BH - Bahrain 2
BO - Bolivia 2
CR - Costa Rica 2
GT - Guatemala 2
GY - Guiana 2
HU - Ungheria 2
JM - Giamaica 2
KH - Cambogia 2
KZ - Kazakistan 2
ML - Mali 2
MM - Myanmar 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BW - Botswana 1
BZ - Belize 1
ET - Etiopia 1
GP - Guadalupe 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MC - Monaco 1
Totale 17.971
Città #
Singapore 1.304
Southend 1.025
Fairfield 854
Ashburn 567
Santa Clara 534
Woodbridge 383
Chandler 376
Seattle 375
Wilmington 366
Houston 358
Hong Kong 344
Cambridge 310
San Jose 307
Princeton 277
Hefei 261
Ho Chi Minh City 255
Dong Ket 238
Ann Arbor 214
Hanoi 209
Jacksonville 201
Beijing 196
Dublin 162
Boardman 157
Lauterbourg 133
Nanjing 122
Westminster 111
Tokyo 106
Padova 101
Berlin 91
Seoul 90
Helsinki 78
Los Angeles 74
Bologna 62
Jinan 62
Buffalo 57
Shenyang 55
San Diego 54
Milan 52
Da Nang 47
Abidjan 46
Dallas 45
Saint Petersburg 45
Turin 45
Council Bluffs 44
Hebei 41
Changsha 39
Mülheim 39
New York 38
Nanchang 37
Redondo Beach 36
Dearborn 35
Munich 35
Amman 34
Frankfurt am Main 34
Lomé 33
Chicago 30
Des Moines 27
Redmond 27
Can Tho 26
The Dalles 25
Zhengzhou 25
Bengaluru 23
Bremen 23
Mahé 23
Bern 22
Shanghai 22
São Paulo 22
Brussels 21
Moscow 21
Tianjin 21
Haiphong 20
Al Mansurah 19
Guangzhou 18
Hangzhou 18
Verona 18
Johannesburg 17
Lanzhou 17
London 16
Rome 16
Jakarta 15
Kunming 15
Norwalk 15
Taizhou 15
Bangkok 14
Bühl 14
Medford 14
Cesena 13
Montreal 13
Nuremberg 13
Vienna 13
Baghdad 12
Biên Hòa 12
Cebu City 12
Chengdu 12
Falls Church 12
Jiaxing 12
Phoenix 12
Sofia 12
Thái Nguyên 12
Toronto 12
Totale 11.985
Nome #
D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications 502
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). 303
Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis 248
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. 245
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. 211
Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. 202
Long-term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke. 198
Hereditary thrombophilia and fetal loss: a prospective follow-up study. 197
Age and gender specific cut-off values to improve the performance of D: -dimer assays to predict the risk of venous thromboembolism recurrence. 193
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. 190
A new rapid bedside assay for D-dimer measurement (Simplify D-dimer) in the diagnostic work-up for deep vein thrombosis. 189
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study 180
D-Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal. 177
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. 175
A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. 175
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study 172
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study 172
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. 170
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register 166
Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. 165
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis 164
Familial thrombophilia and lifetime risk of venous thrombosis 162
Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting 160
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism 159
Bridging therapy in oral anticoagulated patients: focusing on how to do it. 158
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 158
Analysis of agreement between duplex ultrasound scanning and arteriography in patients with lower limb artery disease 157
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. 157
A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage. 157
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 156
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 155
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 155
Diagnosis of deep vein thrombosis. 152
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in hemodialysis patients 152
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. 151
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome 151
External validation of the DASH prediction rule: a retrospective cohort study 151
Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital 148
Lo studio BAFTA [The BAFTA study] 148
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 147
D-dimer testing and venous thromboembolism: four view points 145
Predictors of psychological state after genetic testing for inherited thrombophilia 145
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. 144
Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. 143
Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation population: The Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study 143
Fibrin D-dimer testing for venous and arterial thrombotic disease 142
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: A prospective multicenter study 142
HemosIL D-dimer HS assay in the diagnosis of deep vein thrombosis and pulmonary embolism. Results of a multicenter management study. 141
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. 140
Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale. 139
D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. 138
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. 138
Predicting the risk of recurrence of venous thromboembolism. 138
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. 138
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms 137
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. 136
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the Prolong extension study. 136
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. 129
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 128
VASCULAR ENDOTHELIAL DYSFUNCTION IN PRIMARY OPEN ANGLE GLAUCOMA 128
Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). 127
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. 126
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants 126
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). 126
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. 126
D-dimer, oral anticoagulation, and venous thromboembolism recurrence 124
D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results 123
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? 123
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. 123
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 122
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothrombin time monitor (COAGUCHECK) 122
The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). 121
Risks factors for highly unstable response to oral anticoagulation: a case-control study. 121
Extended treatment for venous thromboembolism: how long is long enough? 120
Warfarin anticoagulation in children made easier. 120
PROFILASSI DELLA MALATTIA TROBOEMBOLICA VENOSA IN CHIRURGIA BARIATRICA: STUDIO PROSPETTICO RANDOMIZZATO DI CONFRONTO TRA DUE DIFFERENTI DOSAGGI DI PARNAPARIN 119
Recurrence rate after a first venous thrombosis in patients with familial thrombophilia 119
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. 117
Predictors of psychological state after genetic testing for inherited trombophilia 116
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. 116
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 116
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register 116
D-dimer testing to determine the duration of anticoagulation therapy. 115
Modulation of factor V levels in plasma by polymorphisms in the C2 domain. 114
Risk factors for venous thromboembolism in the elderly: results of the master registry. 114
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 113
Venous thromboembolism in renal transplant recipients: Results of Venous thromboEmbolism in renal Transplant Recipients- Italian Study - VETRIS 113
Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register 113
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis 111
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia 111
Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. 110
The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. 110
Psychological impact of testing for thrombophilic alterations. 110
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 110
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs 110
D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-Vitamin K anticoagulants 110
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants 109
Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum) 108
Emerging drugs for venous thromboembolism. 108
Old and new heparins. 106
Totale 14.762
Categoria #
all - tutte 49.255
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.255


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021605 0 0 0 0 0 0 0 0 0 117 84 404
2021/20221.870 199 59 169 125 224 109 49 164 70 86 273 343
2022/20231.923 244 278 112 252 119 148 53 89 285 68 175 100
2023/2024381 30 77 37 36 30 30 23 29 12 34 18 25
2024/20252.930 66 484 150 183 763 140 179 34 65 239 114 513
2025/20265.293 359 661 577 430 758 399 528 293 931 357 0 0
Totale 18.310